Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment

Presse Med. 2021 Jun;50(2):104069. doi: 10.1016/j.lpm.2021.104069. Epub 2021 Jul 13.

Abstract

Multiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age of Onset
  • Child
  • Child, Preschool
  • Cognition Disorders / etiology
  • Demyelinating Autoimmune Diseases, CNS / diagnosis
  • Diagnosis, Differential
  • Early Diagnosis
  • Female
  • Fingolimod Hydrochloride / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Infant
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis* / diagnosis
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / epidemiology
  • Natalizumab / therapeutic use
  • Sphingosine 1 Phosphate Receptor Modulators / therapeutic use
  • Symptom Assessment

Substances

  • Immunologic Factors
  • Natalizumab
  • Sphingosine 1 Phosphate Receptor Modulators
  • Fingolimod Hydrochloride